SAN DIEGO--(BUSINESS WIRE)--PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO).

圣地亚哥--（商业新闻短讯）--PharmaLegacy Laboratories是体外和体内临床前药物开发服务的提供商，已收购BTS Research，这是一家总部位于圣地亚哥的临床前合同研究组织（CRO）。

As a reputable CRO providing preclinical pharmacology services to clients worldwide, PharmaLegacy’s acquisition of BTS Research is an important step in its continuing growth. San Diego is a significant global R&D hub and the acquisition allows PharmaLegacy to join the greater community while also strengthening and expanding PharmaLegacy’s global research capabilities and service offerings..

作为一家为全球客户提供临床前药理学服务的知名CRO，Pharmalegage收购BTS Research是其持续增长的重要一步。圣地亚哥是一个重要的全球研发中心，此次收购使PharmaLegacy加入了更大的社区，同时也加强和扩大了PharmaLegacy的全球研究能力和服务产品。

“PharmaLegacy has been serving the US markets for many years, and a local presence in San Diego biotechnology scene will accelerate our growth,” said Jeff Duan, founder & CEO of PharmaLegacy. “This acquisition will allow us to better serve clients across the US and North America while increasing our study capacity and providing more flexibility for all of our clients.

PharmaLegacy创始人兼首席执行官杰夫·段（Jeff Duan）表示：“PharmaLegacy多年来一直为美国市场服务，在圣地亚哥生物技术领域的本地业务将加速我们的增长。”。“此次收购将使我们能够更好地为美国和北美的客户服务，同时提高我们的学习能力，并为所有客户提供更大的灵活性。

As such, it is a crucial step to becoming an industry-leading preclinical CRO.”.

因此，这是成为行业领先的临床前CRO的关键一步。”

The synergy between PharmaLegacy and BTS Research creates a powerful combination that will further allow pharmaceutical, biotechnology, medical device, and diagnostics companies to obtain rapid and reliable pharmacology data to advance cures for patients. The combined companies possess decades of experience providing preclinical research services, and the acquisition of BTS will allow PharmaLegacy to add GLP toxicology services to our complete offering of pharmacology services..

PharmaLegacy和BTS Research之间的协同作用创造了一个强大的组合，将进一步使制药，生物技术，医疗器械和诊断公司获得快速可靠的药理学数据，以促进患者的治疗。合并后的公司拥有数十年提供临床前研究服务的经验，收购BTS将使Pharmalegage能够将GLP毒理学服务添加到我们完整的药理学服务中。

“We are truly excited to be joining the PharmaLegacy family,” said Sami Abunadi, President of BTS Research. “As we further integrate our capabilities and knowledge, we will be able to deliver best-in-class research services to support drug, device, and diagnostic pipelines. This joining of forces will create a highly competitive global CRO.”.

BTS Research总裁萨米·阿布纳迪（SamiAbunadi）表示：“能够加入PharmaLegacy家族，我们真的很兴奋。”。“随着我们进一步整合我们的能力和知识，我们将能够提供一流的研究服务，以支持药物，设备和诊断管道。这种力量的结合将创造一个极具竞争力的全球CRO。”

PharmaLegacy is a CRO founded in 2008 which provides efficient and cost-effective preclinical in vitro and in vivo pharmacology studies to life science organizations. PharmaLegacy boasts a thousand of validated in vitro and in vivo services across over 40 different diseases, and has contributed to over 400 IND applications..

PharmaLegacy是一家成立于2008年的CRO，为生命科学组织提供高效且具有成本效益的临床前体外和体内药理学研究。PharmaLegacy拥有超过40种不同疾病的数千种经过验证的体外和体内服务，并为400多种IND应用做出了贡献。

For more information on PharmaLegacy, visit https://www.pharmalegacy.com/

For more information on PharmaLegacy, visit https://www.pharmalegacy.com/

BTS Research is a San Diego-based Contract Research Organization that delivers GLP and Non-GLP biological services to clients in pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and related industries, and has roots dating back to 2001 (formerly Bio-Quant, Inc. and BioTox Sciences).

BTS Research是一家总部位于圣地亚哥的合同研究组织，为制药、生物制药、生物技术、学术研究、医疗器械和相关行业的客户提供GLP和非GLP生物服务，其历史可追溯到2001年（前身为Bio Quant，Inc.和BioTox Sciences）。

The Company was founded in 2007 and acquired Bio-Quant in 2011..

该公司成立于2007年，并于2011年收购了Bio Quant。

For more information on BTS Research, visit https://btsresearch.com/

有关BTS研究的更多信息，请访问https://btsresearch.com/